We understand that it can be challenging to gain clarity and perspective on breaking Parkinson's news. Q&As in this section are conducted with leading experts in the Parkinson's disease research field to quickly provide an informed, impartial opinion on new findings -- and to get to the bottom of what they might mean for researchers and people living with PD today.
Read a Q&A with Jeff Conn on His Team's Milestone in Pursuit of a Glutamate-based Therapy for Parkinson's disease
September 30, 2009
On Wednesday, September 30, Jeff Conn, PhD, announced at The Michael J. Fox Foundation's third annual PD Therapeutics Conference that his MJFF-funded team at Vanderbilt Medical Center had hit a major milestone in its pursuit of a new class of glutamate-based therapies for Parkinson's disease. The Foundation spoke to him about what his team has achieved and the possible implications for Parkinson's patients.
MJFF: When we talk about ways to improve treatments for PD and create new ones, we are...
From Teva's ADAGIO Trial: Inconclusive Results, but Possible Disease-modifying Effect, for Azilect (Rasagiline)
September 23, 2009
This week, the New England Journal of Medicine published data from the ADAGIO Phase 3 clinical trial of Israeli drugmaker Teva's Azilect (rasagiline). The trial was designed to test whether Azilect, which is already approved for symptomatic treatment of Parkinson's, may also have a disease-modifying effect. For early-stage PD patients, a 1-milligram dose of Azilect met all three clinical endpoints for disease modification. However, a 2-milligram dosage met only two of three endpoints. Because of...Read More
New England Journal of Medicine Opinion Papers on Genes and Disease: Analysis and Implications for PD Genetics Research
April 21, 2009
On April 15 opinion papers published in the New England Journal of Medicine (NEJM) received worldwide press for their position statements on genes' limited ability to predict human disease. Brian Fiske, PhD, MJFF's associate director, team leader, research programs, provides analysis of the papers and their implications for ongoing research into the genetics of Parkinson's disease.
Q: Newspaper articles and the NEJM papers themselves seem to say that genes are not that useful in predicting d...
Spinal Shocks Alleviate Parkinson's Symptoms in Pre-clinical Models: What Does It Mean for People with PD?
March 26, 2009
In March 2009, researchers at Duke University reported in the journal Science that by electrically stimulating the spinal cords of rodents, they had reversed some of the worst symptoms of Parkinson's disease. The Michael J. Fox Foundation spoke to Erwan Bezard, PhD, of the University of Bordeaux (France) about the potential of the work to lead to a novel treatment for people with Parkinson's disease. Dr. Bezard, who sits on MJFF's Executive Scientific Advisory Board, is a leading expert in the b...Read More
President Obama Issues Executive Order on Embryonic Stem Cells: What Does It Mean for Parkinson's Disease Research?
March 09, 2009
On March 9, 2009, President Barack Obama signed an Executive Order that calls for fair and ethical funding and oversight for embryonic stem cell research. In doing so President Obama has reversed previous federal legislation restricting embryonic stem cell research to a limited number of cell lines created before August 2001. The new policy ensures that Americans are no longer forced to look back at what could have been, but can instead look forward to one day seeing the promise of scientific an...Read More